SUMMARY
There has been a dearth of new drugs approved for cardiovascular disorders. The cost is prohibitive, averaging to $2.5 billion, and requiring 12.5 years. This is in large part due to the high failure rate, with only 5% approval by the Food and Drug Administration. Despite preclinical studies showing potential safety and efficacy, most fail when they go to clinical trials phase I to III. One cause for failure is the drug target, often discovered to be a biomarker rather than causative for the disease. Mendelian randomization (MR) studies would determine whether the drug target is causative and could save millions of dollars and time, and prevent unnecessary exposure to adverse drug effects. This was demonstrated in 3 clinical trials that were negative with 2 drugs, veraspladib and darapladib. MR studies during the trials showed the targets of secretory and lipoprotein-associated phospholipids A2 are not causative for coronary artery disease and predicted negative results. The requirement for MR studies is a genetic risk variant with altered function, randomized at conception that remains fixed throughout one's lifetime. It is not confounded by dietary, lifestyle, or socioeconomic factors. It is more sensitive than randomized controlled trials because exposure to the risk factor is fixed for a lifetime.
MR studies showed plasma high-density lipoprotein cholesterol is not a causative target of coronary artery disease, and neither is uric acid, C-reactive protein, and others. MR studies are highly sensitive in determining whether drug targets are causative, and are relatively easy, inexpensive, and not time consuming. It is recommended that drug targets undergo MR studies before proceeding to randomized controlled trials. Mathematical and statistical polygenic models employing large sample sizes have been developed for MR utilizing disease-related genetic variants to determine whether the risk factor contributes to the 
HIGH RATE OF FAILURE FOR DEVELOPMENT OF DRUGS
It is estimated that only about 5% of drugs evaluated in phase I clinical trials are ultimately approved by the FDA (3, 4) . Most failures are said to occur in phase II clinical trials, with about a quarter of the failures due to toxic effects and about one-half due to lack of efficacy (3, 8) . It has long been recognized that the cost of drug development is dominated primarily by the high rate of failures. It is worth noting that the failures in phase II clinical trials occur despite prior extensive evaluation in in vitro and animal studies.
To be evaluated in phase I clinical studies, preclinical studies must show the drug to be safe and effective.
The preclinical studies are claimed to account for 32% of the cost for developing a new drug, and the clinical studies (phase I to III) for approximately 63% (4).
It is evident from the preceding discussion that increased productivity could come from several areas, but low-lying fruit would be attacking the high failure rate. Increased efficiency and productivity should target reducing the failure rate in phase II and phase III clinical trials. In contrast to this, the current trend in the pharmaceutical industry suggests that both phase II and phase III failure rates are increasing (3, 6, 9, 10) . Reduction in either phase II or III by 50% from a baseline value of 2.5 years to Roberts
Mendelian Randomization Studies 4. The disease process does not alter the germline genotype, therefore the association between genetic variant and disease is not influenced by reversed causality.
5. The genetic variant remains fixed throughout life, providing for the assessment of a lifetime exposure.
6. There is no problem with compliance because the genetic variant is fixed for life.
7. Because germline DNA remains unchanged throughout life, there is no regression dilution effect.
MR ¼ Mendelian randomization.
on the assumption that inhibiting the actions of these 2 interleukins would decrease inflammation and be beneficial. However, an increased incidence of MI was observed in part due to increased plasma levels of LDL-C. A subsequent monoclonal antibody specific for IL-1b was associated with decreased CAD and had no effect on lipids or MI. The implication is that IL-1a may have opposing effects such as those mediated through increased plasma lipids (59 Although MR is primarily used to determine causation between the risk factor and the outcome of the disease, it also provides important information on safety and efficacy.
MR INDICATED THE PHOSPHOLIPASE A2 ENZYMES ARE NOT APPROPRIATE DRUG TARGETS FOR PREVENTING CAD
In the search for new drugs to treat CAD, the obser- Analysis showed no effect on outcome, and the trial was discontinued.
Darapladib, an inhibitor of lipoprotein-associated darapladib (160 mg/day) or placebo with a follow-up of 3.7 years (79). There was no effect on death, MI, or stroke in either of these studies. Meta-analysis of both studies showed no statistically significant decreased risk of CAD (78, 79) .
Although clinical trials were being performed to assess the safety and efficacy of veraspladib and darapladib, MR studies were being performed. One MR study used a functional genetic variant of sPLA2 that was associated with 38% lower plasma levels with 1 copy and 60% lower levels with 2 copies. These reductions in sPLA2 were greater than observed with veraspladib or darapladib. In a sample size of 93,000, the MR study showed no evidence of a causal effect of Recently, a monoclonal antibody, canakinumab, was developed which selectively inhibits IL-1b. Preliminary studies showed reduced plasma levels of IL1b, IL-6, and CRP but no effect on IL-1a and no effect 
